anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND OBJECTIVES: Drowning, the leading cause of unintentional injury death among California children less than five years of age, averaged 49 annual fatalities for the years 2010-2021. The California Pool Safety Act aims to reduce fatalities by requiring safety measures around residential pools. This study was designed to analyze annual fatality rates and drowning incidents in California among children 1-4 years of age from 2017-2021.
METHODS: We identified fatalities, injury hospitalizations, and emergency department (ED) visits from California state vital statistics death data and state hospital and ED discharge data using the EpiCenter California Injury Data Online website.
RESULTS: Over the five-year study period, 4,166 drowning incidents were identified: 234 were fatalities, 846 were hospitalizations, and 3,086 were ED visits. The observed difference in fatality rates from 2017 to 2021 failed to achieve statistical significance (P = 0.88). Location-based analysis of the 234 fatal drowning incidents revealed that pools were the most common injury site, accounting for 65% of the cases.
CONCLUSION: Drowning remains the leading cause of unintentional, injury-related death among California children 1-4 years of age, as the annual rate of fatality over the five-year study period did not decline. While the EpiCenter California Injury Data Online website is excellent for analyzing annual rates of drowning incidents among California residents over time, it is limited in providing insight into modifiable risk factors and event circumstances that can further inform prevention. The development of robust integrated fatal and non-fatal local, state, and national systematic data collection systems could aid in moving the needle in decreasing pool fatalities among young children.
Participants received 100 μg (if body weight was ≤60 kg) or 150 μg (if body weight was \>60 kg) of CFA as a subcutaneous (SC) injection once every 2 weeks for 64 Weeks (Day 1, Week 0 through Week 64) and 500-5000 IU of hCG reconstituted with 1 ml of 0.9% sodium chloride solution, as a SC injection twice a week for 52 weeks (last day of Week 12 through Week 64). The total treatment duration was 64 Weeks.
OBJECTIVE: This study assessed the cost-effectiveness of atezolizumab in combination with chemotherapy for patients with advanced or recurrent endometrial cancer (EC) from the U.S. payer's perspective.
METHODS: A cost-effectiveness study was conducted using a Markov model based on ENGOT-en7/MaNGO/AtTEnd clinical trials. The population consisted of patients with EC, stratified by mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) subgroups. The model simulated patients receiving either atezolizumab plus chemotherapy or chemotherapy alone. Cost, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) were calculated using a Willingness-to-Pay (WTP) threshold of $150,000/QALY. Sensitivity analyses were performed.
RESULTS: Adding atezolizumab to chemotherapy in dMMR EC resulted in an incremental gain of 3.31 QALYs but at an additional cost of $855,042, leading to an ICER of $258,391.07/QALY compared to chemotherapy alone. In pMMR EC, there was a gain of 0.50 QALYs with an additional cost of $140,502, resulting in an ICER of $279,239.72/QALY. The overall ICER for EC was $216,459.34/QALY. Scenario analysis indicated that administering atezolizumab for a maximum of 2 years improved cost-effectiveness in dMMR EC, with an ICER of $70,695.96/QALY falling within the predetermined WTP threshold.
CONCLUSION: For patients with advanced or recurrent EC, the combination of atezolizumab and chemotherapy may not prove cost-effective. However, administering atezolizumab for a limited period of maximum 2 years could improve cost-effectiveness in dMMR EC.
After general anesthesia (GA), patient will be placed in lateral position with side to be anesthetised upwards. U/S probe will be placed in the transverse plane at the abdominal flank immediately cranial to the iliac crest. Then moved dorsally until the QL muscle is identified with its attachment to lateral edge of the transverse process of the L4 vertebral body with identification of shamrock sign. The needle is inserted in-plane to transducer (lateral edge) and tip of needle is advanced through the QL muscle. Once the tip of the needle correctly placed and confirmed by negative aspiration, 2 ml of normal saline will be instilled to confirm correct separation of the plane. Following this, 30 ml of 0.25% bupivacaine will be injected between the QL and psoas major.
Each participant will be administered a single oral 40-mg simvastatin dose on Day 1 and Day 13. The participants will receive TMC435 once daily dose of 150 mg from Day 4 until Day 15.
PURPOSE: A pharmaceutical composition containing fibulin-3 protein is provided to reduce wnt/beta-catenin, MMP2 and MMP7 and to suppress the growth of non-small cell lung cancer cell(A549 cells), breast cancer cells(MDA-MB231 cells), and cancer stem cells(ALDH1-active cells). CONSTITUTION: Fibulin-3 protein suppresses the growth of cancer stem cells. The fibulin-3 protein has an amino acid sequence of sequence number 1. A method for preparing the fibulin-3 protein which suppresses cancer stem cell activation comprises: a step of preparing a vector encoding the fibulin-3 protein; a step of transforming the vector into cells; and a step of purifying the fibulin-3 protein from the cell culture. A pharmaceutical composition for suppressing the growth of cancer stem cells contains the fibulin-3 protein as an active ingredient. The pharmaceutical composition contains fibulin-3 overexpressing cell line or a culture medium thereof as an active ingredient. [Reference numerals] (AA) Fibulin-3
The invention discloses a Chinese medicinal pill for nourishing yin, calming endogenous wind and reducing blood sugar, which is prepared from the following raw materials: the invention relates to a traditional Chinese medicine composition for treating diabetes, which is prepared from 14 traditional Chinese medicines including mother-of-pearl, endothelium corneum gigeriae galli, summer-withered flower, scutellaria baicalensis, mulberry leaf, chrysanthemum, radix rehmanniae, white paeony root, raw oyster, uncaria, sophora flower, raw dragon's bone, liquorice, gynostemma pentaphylla and the like. 1. Has no influence or little influence on normal physiological functions and no toxic or side effect. 2. The effect is nonspecific and broad-spectrum. 3. Has effects in regulating body function, enhancing immunity, lowering blood pressure, and regulating blood sugar. 4. Can effectively improve the clinical symptoms and physical signs of patients, and has therapeutic effect on liver yang hyperactivity and syncope yin diseases.
PURPOSE:To obtain a ferrous salt-containing hair-dyeing agent composition capable of masking the smell of iron rust without deteriorating the hair dyeability by adding a water-soluble zinc compound and glycine to a composition containing the ferrous salt. CONSTITUTION:A composition containing 0.05-2wt.% of a ferrous salt such as ferrous sulfate or ferrous chloride is compounded with 0.01-10wt.% of at least one kind of water-soluble zinc compound (e.g. zinc sulfate, zinc chloride or zinc para phenylsulfonate) and 0.05-10wt.% of glycine, and further suitably compounded with other conventional arbitrary contponents to control the pH of the composition to 3-6. Since the iron rust smell of the composition containing the ferrous salt can effectively masked, the composition is suitable as a hair cosmetic, etc. The dyeability of the composition is further not deteriorated, and the adhesion of the iron rust smell to hair during or after the treatment of the hair is little. The composition does not give an unpleasant feeling.
OBJECTIVE: To evaluate the efficacy of therapeutic interventions on pediatric burn patients' height, weight, body composition, and muscle strength.
METHODS: A systematic literature search was conducted in PubMed, Embase, and Web of Science up to March 2021. Eligible interventional studies reported metrics on the height, weight, body composition, or muscle strength of pediatric burn patients in a peer-reviewed journal. Meta-analyses were performed if ≥ 2 trials of clinical homogeneity reported on an outcome measure at the same time point post-burn.
RESULTS: Twenty-six interventional studies were identified, including twenty-two randomised controlled trials and four non-randomised trials. Most studies were conducted by a single institution. On average, the burn covered 45.3% ( ± 9.9) of the total body surface area. Three categories of interventions could be distinguished: rehabilitative exercise programs, pharmacologic agents, and nutrition support.
CONCLUSIONS: Each of the interventions had a positive effect on height, weight, body composition, or muscle strength. The decision to initiate an intervention should be made on a case-by-case basis following careful consideration of the benefits and risks. In future research, it is important to evaluate the heterogeneity of intervention effects and whether participation in an intervention allowed pediatric burn patients to reach the physical and functional status of healthy peers.
Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanisms. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and alteration of the physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [see ]. Boxed Warning

Consult the labeling of all concurrently used drugs to obtain further information about interactions with warfarin sodium or adverse reactions pertaining to bleeding.
BACKGROUND: Previous studies have suggested a potential association between irritability and the risk of various diseases. However, establishing a causal relationship has remained a significant challenge. To address this issue, we employed Mendelian randomization (MR), a sophisticated approach that leverages genotype data to emulate the conditions of randomized controlled trials. This method enables us to investigate the potential causal link between irritability and the susceptibility to esophageal diseases.
METHODS: We conducted an extensive multivariable MR analysis using summary-level data from genome-wide association studies (GWAS) encompassing various esophageal diseases, including gastroesophageal reflux disease (GERD), esophageal cancer (EC), and Barrett's esophagus. Both univariable and multivariable MR analyses were performed to elucidate and confirm the causal association between genetically predicted irritability and the incidence of esophageal diseases.
RESULTS: Based on our primary causal effects model utilizing MR analyses with the inverse-variance weighted (IVW) method, genetically predicted irritability was identified as a risk factor for GERD (OR = 2.413; 95 % CI: 1.678-3.470; P = 2.03E-06) and Barrett's esophagus (OR = 2.306; 95 % CI: 1.042-5.101; P = 0.039). However, irritability was not found to be associated with the risk of EC, even after adjusting for BMI, smoking initiation, and alcohol consumption.
CONCLUSION: The multivariable MR analysis performed in this study demonstrated a causal relationship between irritability and esophageal diseases. It is imperative to acknowledge the need for further large-scale prospective studies to validate these findings.
Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al (2D Fluoroscopy). After the attending surgeon is satisfied with the reduction quality, 3D fluoroscopy will be used to generate additional images to assess syndesmotic and fibular reductions. Both 2D and 3D Fluoroscopy will be performed using device "Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system".
Studies report as many as 1 out of every 5 Americans is affected by mild to severe Seasonal Affective Disorder (SAD, winter depression). Although the exact cause of this condition is unknown, bright light has proven to be an effective therapeutic treatment for many people with SAD. The light sources that have been traditionally used for treatment of SAD produce white light with great variability in the balance of wavelengths that are emitted across the visible spectrum. Although several studies have attempted to test the effectiveness of different wavelengths for treatment of SAD, the devices used in those studies employed broad bandwidths of light. With the technological advancements in light emitting diodes (LEDs) the production of new light therapy equipment with much narrower bandwidths of light is possible. Side effects of exposure to traditional white light therapy for SAD have included hypomanic activation, irritability, headache, eyestrain and nausea. We hypothesize that when the wavelength of light therapy is optimized, it should be feasible to elicit strong therapeutic benefits with lower light intensities and fewer side effects. Previous studies, approved by the Jefferson IRB and successfully completed by our laboratory have shown that some colors of light are more effective in treating SAD than other colors.
The inflammatory response after major abdominal surgery is of great importance for patients, physicians and perioperative medicine1. Perioperative excessive stimulation of the inflammatory and hemostatic systems may result in development of postoperative ileus, ischemia-reperfusion syndromes, hypercoagulation syndromes (e.g. deep venous thrombosis) and pain excessive inflammatory response such as impaired gastrointestinal motility, so modulation of inflammatory responses may decrease severity of such complications 2,3.

Intravenous lidocaine, a local anesthetic, has been shown to improve postoperative analgesia, reduce postoperative opioid requirements, accelerate postoperative recovery of bowel function, attenuate postoperative fatigue, reduced the duration of hospitalization, and facilitate acute rehabilitation in patients undergoing laparoscopic abdominal surgery 4. Administration of local anesthetics to epidural space has analgesic effect, blunt stress response; provide rapid mobilization, early extubation with rapid recovery of bowel function 5. However, insertion of an epidural catheter carries risks especially in pediatric populations. So, systemic lidocaine may become another strategy for improving perioperative outcome which is safe and effective2.
Pemetrexed and cisplatin will be admixed together in 1 liter of normal saline. The admixture of pemetrexed/cisplatin is stable for 4 hours and should be prepared and delivered immediately before use in the OR. The length of the pemetrexed/cisplatin lavage will be 1 hour.
Autoantigen vaccines are obtained by conferring antigenicity by formation of multimers, of fusion proteins to non-bacterial sequences, or both. The vaccines can be administered using conventional dosage forms for peptide vaccines, or can be supplied in a recombinant vaccinia and the peptides synthesized in situ. Particularly useful autoantigens are those derived from hormones controlling reproduction. An easily administered and reversible vaccine for preventing human pregnancy is disclosed. The vaccine comprises a vaccinia virus vector modified to contain the DNA sequence encoding the C-terminal portion (CTP) of the beta-chain of human chorionic gonadotropin, or a multimer thereof. The vaccinia vectors are designed so that the encoded antigen is expressed internally by infected cells, or the CTP-encoding sequence is modified to provide a chimera which is capable of carrying the CTPn antigen to the surface of the infected cell and either presenting the CTPnantigen at the cell surface or of secreting it. In a preferred embodiment, the influenza hemagglutinin protein, or portions thereof, are used as the components of the chimera. Similar constructions which include alternate hormone derived sequences are also effective in humans and in other mammals. The antibodies obtained against and specific for these autoantigens are also useful.
FIELD: medicine. SUBSTANCE: preparation has insulin and a substance increasing its absorption in inferior respiratory tracts. The preparation is produced as dry powder usable for making inhalations. The powder has at least 50% by mass of insulin and a substance increasing its absorption as particles of up to 10 mcm diameter or agglomerates composed of such particles. The powder has a pharmacologically acceptable carrier. Bull, pig insulin, biosynthetic or semisynthetic human insulin or biologically active insulin derivative is to be taken as insulin. Surfactant substance, biliary salt, biliary salt derivative, sodium salt of urosodesoxycholate, taurocholate, glycocholate, taurodihydrofusidate, phospholipid, alkyl glycoside and others are to be taken as the substance increasing insulin absorption in inferior respiratory tracts. The preparation can be placed in inhalation device. The method involves producing insulin solution with a substance increasing its absorption in inferior respiratory tracts. The solvent is removed and powder is obtained. The powder has at least 50% of particles having their diameters less than 10 mcm. Solid state product is obtainable, the product being crushed and/or mixed to produce the powder. The second version of the method involves mixing dry insulin with dry substance increasing its absorption. Powder is produced that has at least 50% of particles having their diameters less than 30 mcm. First of all, a mixture is optionally produced. The mixture is comminuted and/or mixed until the powder is produced. Mixing is done also in the presence of carrier. EFFECT: reduced discomfort and uneasiness manifestations in treating patients with insulin. 41 cl, 9 dwg, 3 tbl
Patients received oral apatinib 500 mg in tablet once daily. Patients also received oral S1 in capsule 40-60mg bid, days 1-14. A treatment cycle was defined as 21 days (3 weeks).
INTRODUCTION: The epidemiological evolution of bloodstream infections (BSIs) in the last decade is not clearly defined. Our aim was to analyze the changes in the workload in our institution and to describe the evolution of the incidence and etiology of BSIs in a 12-year period, including the COVID-19 pandemic.
METHODS: All blood cultures received in the laboratory of a tertiary general hospital between 2010 and 2021 were analyzed. Bloodstream infection episodes refer to each episode of bacteremia or fungemia in each patient. Incidence rates per 1000 admissions and per 100,000 population were calculated.
RESULTS: No significant changes in the incidence of BSI episodes/1000 admissions were observed (mean, 31.1), while estimated population-based incidences showed declining trends (mean, 182.8/100,000 inhabitants). There was a slight increase in BSI episodes per 1000 admissions caused by Gram-negatives (mean, 16.6/1000 admissions) and E. coli was the most frequent pathogen (mean, 8.5/1000 admissions). There was no significant rise in episodes caused by ESBL- and carbapenemase-producing E. coli or K. pneumoniae, with a decline in those caused by methicillin-resistant S. aureus. A spike in BSI episodes, fungal BSIs and catheter-related infections was detected in 2020, during the COVID-19 outbreak.
CONCLUSIONS: No clear increase in the incidence of BSI episodes was detected in our center over this period. Gram-negatives are the most frequent etiology, with no clear rise in antimicrobial resistance phenotypes. The COVID-19 pandemic accounted for a small increase in BSI episodes in 2020, probably related to the increase of catheter-related infections.
Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months). Participants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).
The objective of the present invention is to provide a drug effective for treating skin inflammation with negligible or no adverse side effects. The present invention relates to an anti-inflammatory pharmaceutical composition containing a cell-permeable thioredoxin 1 (Trx1) fusion protein. The Trx1 fusion protein penetrated into a cell increased the cell survival rate against hydrogen peroxide toxicity; reduced the level of reactive oxygen species, thereby performing cytoprotective actions; and significantly reduced the LPS-induced COX2 and iNOS protein expression levels in a dose-dependent manner. In addition, Tat-Trx1 fusion protein suppressed inflammatory reactions induced by high-concentration LPS. In addition, the Tat-Trx1 fusion protein: significantly suppressed the inflation of inflammatory cells such as monocytes, which occur early in skin inflammation; significantly reduced the COX-2 expression level and the production of TNF-α, IL-1β, and IL-6 in a TPA-induced animal inflammation model; and suppressed phosphorylation of p38, ERK, and JNK, and phosphorylation of p65 and IkB α in a TPA-induced skin inflammation animal model such that the permeated Tat-Trx1 fusion protein suppressed an apoptosis pathway. Accordingly, it is shown that the permeated Tat-Trx1 fusion protein has the effects of: protecting cells from apoptosis; and treating skin inflammation.
PURPOSE: To evaluate the surgically induced astigmatism over a 6-month follow-up period in patients who underwent scleral IOL fixation using an acrylic single-piece IOL with special haptics designed for sutureless scleral fixation.
METHODS: We conducted a prospective longitudinal study at a single site with a single surgeon. We included patients who received transscleral IOL implantation following the Carlevale technique and were followed up post-operatively for 24 weeks. We measured the patient's refraction at baseline, week 12 and week 24 using the best corrected visual acuity at 4 m (EDTRS chart). We performed corneal tomography at every visit using an anterior segment optical coherence tomography (AS-OCT). We evaluated surgically induced astigmatism (SIA) and refraction during each follow-up visit and compared them to baseline. We then assessed changes in SIA over time.
RESULTS: In total, 27 eyes of 27 patients consisting of 16 female and 11 male individuals were evaluated. The mean patient age was 71 ± 11.7 years, mean axial length was 24.30 ± 1.47 mm (range: 21.4-27.23) and mean white-to-white distance was 12.07 ± 0.40 mm (range: 11.4-12.7). The mean SIA decreased from 1.78 ± 0.96D at week 1 significantly to 0.80 ± 0.55D at week 12 (p < 0.001) and then stayed unchanged around 0.82 ± 0.72D at week 24 (p = 1.0).
CONCLUSIONS: The scleral fixated Carlevale IOL and its implantation procedure were found to result in a predictable SIA of <1D after 24 weeks. However, the axis orientation of the SIA appeared to be random, making it unsuitable for implementation in toric IOL calculations.